dC) displayed no appreciable impact on the observed maintenance of marker gene 48 expression, while the chondrogenic differentiation capacity was compromised. On the 49 other hand, the pre-cultivation with 5-aza-dC improved the osteogenesis and carboxylcytosine have been found [4] . These further modifications of 5mC (5-75 methylcytosine) are catalyzed by the TET family (ten-eleven translocation). 76
Caused by the withdrawal of tissue specific microenvironmental cues, cells de-77 differentiate upon in vitro cell culture, reflecting the loss of tissue specificity. The de-78 differentiation process of isolated human chondrocytes affects the epigenetic pattern 79 of the cells on DNA methylation and histone modification level [5, 6] . Alterations in DNA 80 methylation are also identified in comparative studies of healthy chondrocytes with 81 cells from osteoarthritic tissues [7, 8] . 82
Osteoarthritis (OA) is the most common disease of the osteochondral unit. OA is 83 characterized by loss of permanent cartilage, reduced joint spaces, osteophyte 84 development, subchondral bone cyst formation, and sclerosis. To compensate for the 85 loss of matrix integrity, clusters of proliferating chondrocytes emerge in early 86 osteoarthritic cartilage. The proliferation of hitherto resting articular chondrocytes is 87 initiated by changes in the environment of the pericellular matrix (PCM). The disruption 88 of the connection between chondrocytes and their PCM compromise the HA-CD44 89 signaling (hyaluronan and its receptor) and results in the up-regulation of MMPs with 90 a decreased survival of cells [9] . With disease progression, fissures in the cartilage 91 ECM can be detected. The degradation leads to an increase in oxygen tension that 92 further accelerates the process of tissue destruction. Subsequently, the subchondral 93 bone layer is affected, marked by tissue mass reduction. Furthermore, the subjacent 94 calcified layer expands into the articular zone, and tissue vascularization is induced in 95 late OA stages. The disease does not only affect the osteochondral unit of the joint but 96 also the ligaments and the synovium [10] . Pharmaceutical intervention is the only 97 option for patients to reduce pain since OA is not curable. In late state OA, the 98 replacement of the joint by surgery is the only option for patients. Tissue 99
To assess the impact on regenerative applications, we analyzed the influence 124 of a DNMT inhibitor on chondrocytes isolated from patients with late-stage OA. The 125 differentiation potential towards adipogenic, osteogenic and chondrogenic lineages 126 was tested, and DNA methylation levels for specific target sites were analyzed. 127 128 Methods 129 5-aza-dC was added every 24h, while the complete medium exchange was performed 148 every other day. 149
Osteogenic differentiation 150
Cells were seeded in 6-well plates (2.5 x 10 5 /well) and media was changed to 151 osteoblast inducing conditions by adding 10 mM beta-glycerophosphate, 10 nM 152 cholecalciferol (vitamin D3), 100 μM ascorbate phosphate and 10 mM dexamethasone 153 in final concentrations for 28 days. The medium was changed every other day. 154
Differentiation was visualized by Alizarin Red staining and confirmed with qPCR by 155 testing mRNA level for osteopontin (OPN). 156
Alizarin Red staining 157
The medium was carefully aspirated from cell culture wells and washed twice with 158 dH 2 O. Alizarin Red solution (2% in dH 2 O at pH 4.1-4.3) was applied to the wells and 159 incubated at room temperature for 5-10 minutes. The staining solution was removed 160 carefully, and wells were gently washed twice with dH 2 O. Pictures were taken 161 immediately. 162
Adipogenic differentiation 163
Cells were seeded in 6-well plates (2.5 x 10 5 /well), and media was changed to 164 adipogenic inducing conditions by adding 10 μg/ml insulin, 500 μM 3-isobutyl-1-165 methylxanthine, 0.2 mM indomethacin and 1 μM dexamethasone in final 166 concentrations for 28 days. The medium was changed every other day. Differentiation 167 was visualized by Oil Red O staining and confirmed with qPCR by testing mRNA level 168 for fatty acid binding protein 4 (FABP4). 169
Oil Red O staining 170
For visualizing lipid vesicles in the cells, the media was removed, and cells were gently removed, and wells were washed using PBS first and 60 % isopropanol last. Afterward, 173 the wells were emptied to dry completely. Three parts of the Oil Red O stock solution 174 (3% in isopropanol) were mixed with 2 parts of dH 2 O before staining to prepare the 175 staining solution. After 10 min, the working solution was filtered and added to the dried 176 wells for 10 min. The staining solution was removed, and cells were gently washed 177 four times with dH 2 O and drying needed to be prevented. Staining was examined under 178 the microscope and pictures were taken. 179
Chondrogenic differentiation 180
Cells were seeded in a 24-well ultra-low attachment plate (10 6 cells/well, Corning) in 181 DMEM supplemented with 10 % FBS and 1% penicillin/streptomycin. During this 182 cultivation step, the cells undergo mesenchymal condensation forming one self-183 organized aggregate. After condensation is completed (1-2 weeks), media was 184 changed to chondrogenic conditions using serum-free DMEM (1 % 185 penicillin/streptomycin) with 100 nM dexamethasone, 200 nM ascorbate phosphate, 186 40 μg/ml L-proline, 100 μg/ml sodium pyruvate, 1 % ITS-Premix and 10 ng/ml TGF- and stored at -80 °C. Tissue was cut at -16 to -18 °C using a specialized knife for hard 195 tissues and 8 μm sections were placed on glass slides (Histobond, Marienfeld, cut at a thickness of 25-30 μm and were collected in 2 ml centrifuge tubes. 1 ml QIAzol 198 (Qiagen, Germany) was added, and RNA samples were stored at -80 °C until 199
extraction. 200
Alcian blue staining 201
Sample slides were thawed at room temperature for 30 min and then fixed in 10% 202 formalin for 10 min. After fixation was completed slides were brought to dH2O and then 203 incubated in 3 % acetic acid for 3 min. Alcian blue staining using 1% Alcian blue 8G 204 (Sigma Aldrich) in 3% acetic acid at pH 1.5-2.5 for 15-20 min was followed. Slides were 205 washed in water than dehydrated and mounted. Glycosaminoglycans (GAG) were 206 stained in turquoise to light blue. 207
Safranin O / Fast green staining 208
Sample slides were thawed at room temperature for 30 min and then fixed in 10% 209 formalin for 10 min. Slides were stained for 10 min in freshly mixed Weigert's iron 210 hematoxylin solution (Roth). To differentiate the color slides were washed in running 211 tap water for 10 min. Nuclear counterstain was performed by adding slides to Fast 212 green solution (0.05% in dH 2 O) for 5 min. Sections were shortly (10 sec) rinsed with 213 1% acetic acid and then stained with Safranin O (0.1% in dH 2 O) for 5 min. Slides were 214 dehydrated and mounted. Glycosaminoglycans were stained in red, nuclei in black and 215 cytoplasm in light green. 216
GAG measurement 217
The content of glycosaminoglycans (GAG) was measured using DMMB staining (1,9 218 dimethyl methylene blue). Therefore, condensates were first digested overnight at 219 56°C in 700 μl digestion buffer (50 mM Tris-HCl, 10 mM Na Cl, 3 mM MgCl2, 1% Triton 220 X 100 at pH 7,9) containing proteinase K (50 ng/ml). The Digestion was stopped at 90 221 isolate genomic DNA (Macherey Nagel, NucleoSpin Tissue Kit) the other half was 223 further processed by digesting DNA with 3 units of DNase I at 37 °C overnight. The 224 sample was centrifuged at 13,000 xg for 20 min, and the supernatant was divided into 225 three samples of 100 μl each. 1 ml of DMBB solution (0.0016% DMBB, 5% EtOH, 0.2 226 M GuHCl, 0,2 % sodium formate and 0.2% formic acid, adjusted to pH 1.5 with HCl) 227 was added to each 100 μl sample and were incubated for 30 min on shaker. The color 228 complex was pelleted by centrifuging at 12,000 xg for 10 min. The supernatant was 229 removed, and the pellet was resuspended on a shaker for 30 min by adding 300 μl 230 DMBB de-complexation solution (4 M GuHCL in 50 mM sodium acetate (pH 6.8) + 231 10% 1-propanol). OD at 656 nm was measured in triplicates. Standard series of 232 chondroitin sulfate in DMBB de-complexation solution (0-60 μg/ml) was performed for 233 quantification. Column isolated DNA was quantified spectrometrically with the 234 NanoDrop2000 (Thermo Scientific, USA) and glycosaminoglycan values were 235 presented as ratio normalized to DNA content of related samples. 236
RNA isolation 237
Adherent cells were lysed directly on the plate or after collection. Total RNA was 238 extracted and purified using Nucleospin RNA II Kit (Macherey-Nagel, Germany) 239 according to manufacturer protocol. For RNA isolation from cell condensates, samples 240
were snap frozen and cut in 25-30 μm sections before lysis. Sections were transferred 241 to 1 ml QIAzol (Qiagen) and stored at -80 °C until isolation. Phenol/chloroform 242 extraction of total RNA was performed. RNA pellets were resuspended in 20-60 μl 243
RNase free water depending on pellet size. RNA content was measured 244 spectrometrically at 260 nm using NanoDrop2000 (Thermo Scientific, USA).
Genomic DNA was extracted with the NucleoSpin Tissue Kit (Macharey Nagel) 247 according to the manufacturer´s protocol. DNA was eluted in 60 μl dH 2 O measured 248 spectroscopically and stored at -20 °C. 249
Bisulfite sequencing of PECAM promoter 250 500 ng of genomic DNA was bisulfite converted using EZ DNA Methylation Gold Kit 251 (Zymo Research Europe, Germany). The Sequence of the proximal promoter of 252 PECAM was obtained from the UCSC genome browser (human genome assembly 253 hg18). All cytosine bases not in a CpG dinucleotide context were converted to thymine 254 in a text editor, and PCR primer were designed on the converted template using the 255 primer3 software [19, 20] . The PCR product was spanning the promoter from -164 bp 256 to +285 bp regarding transcriptional start. 257
Proliferation assay 258
Cells were harvested by trypsinization, washed twice with PBS and prepared in a cell 259 density of 2 x 10 6 cells/ml. A 2X CFDA-SE (10 μM) working solution was prepared. 260
Equal volumes of cell suspension and the 2X working solution was mixed and 261 incubated for 7 min at room temperature away from light. Labeling was stopped by 262 adding 5 volumes of cold growth medium and incubation of 5 min on ice in the dark 263 followed. Cells were centrifuged and washed twice with growth medium and then 264 seeded in desired density to perform the assay. For the non-proliferating control cells 265 were seeded at a high density to exclude cell proliferation by contact inhibition. Other 266 wells were seeded at 20 % confluence to monitor cell doublings and were treated with 267 0.5 to 5 μM 5-aza-2´-deoxycytidine (Sigma Aldrich). Interestingly, the impact on marker molecule expression seems to be bivalent (Fig 1) . 286
Although both tested isoforms of transcription factor SOX5 were down-regulated and 287 the ECM molecule encoded by COL2A1 was not even detectable after cultivation, the 288 mRNA levels for the cartilage-specific markers SOX6, SOX9, ACAN and PRG4 289 (proteoglycan 4) were unaffected after several weeks of cultivation. 290
The impact of DNA methylation on marker gene expression was assessed by treating 291 cultivated chondrocytes with the DNMT inhibitor 5-aza-2´-deoxycytidine. The treatment 292 with 1 μM 5-aza-dC did not alter the expression of SOX5L (isoform b), SOX6, SOX9, 293 PRG4, and ACAN. Only SOX5M (isoform a) was further down-regulated after 5-aza-dC administration. COL2A1 was not re-expressed after the treatment with the DNMT 295 inhibitor (Fig 1) . 296
Articular chondrocytes do not proliferate in their natural environment, but the cells re-297 enter the cell cycle after isolation and in vitro cultivation. Significant proliferation 298 inhibition in chondrocytes was observed in our experiments with as little as 0.5 μM 5-299 aza-dC in the growth medium with no further gain of the effect between 2 and 5 μM 5-300 aza-dC after 8 days or 0.5 and 1 μM after 16 days of treatment (Fig 2) . 301
Upon de-differentiation, the cells regain mesenchymal stromal cell properties like 302 multiple differentiation potentials. To assess the influence of the DNMT inhibitor 303 treatment, the capacity for adipogenic, osteogenic and chondrogenic differentiation 304 was determined in the respective cells. Compared to the untreated control adipogenic 305 and osteogenic differentiation was further improved by 5-aza-dC treatment (Fig 3 and  306   4 ). The staining of the calcified matrix by Alizarin Red as well as lipid vesicles by Oli 307
Red O staining was positive for both populations after differentiation. However, DNMT 308 inhibitor treated cells displayed a more pronounced lipid vesicle staining and higher 309 expression of fatty acid binding protein-4 (FABP4). Furthermore, gene expression of 310 osteopontin (OPN) showed increased levels after osteogenic differentiation in cells 311 pre-treated with 5-aza-dC (Fig 4) . 312
The most striking difference upon 5-aza-dC administration was observed during 313 chondrocyte differentiation. Although no changes in cartilage marker expression were 314 seen after 5-aza-dC treatment (Fig 1) , the chondrogenic differentiation capacity was 315 significantly compromised upon 5-aza-dC treatment ( Fig 5) . The stimulus of 3D culture 316 and chondrogenic media was not sufficient to induce proper cartilage matrix formation 317 (Fig. 5a ), and glycosaminoglycan (GAG) content was significantly reduced (Fig 5b) . differentiation reduced the cartilage marker expression ( Fig 6) . These data strongly 320 indicate that DNMT inhibition impaired a regulator of cartilage formation, whose activity 321 is essential for active chondrogenic differentiation and assumedly dispensable for 322 phenotype maintenance. 323
To assess the effect of DNMT inhibitor treatment on the DNA methylation status, the 324 global DNA methylation level was determined comprehensively. As seen in Fig 7, Several publications report of de-differentiation and loss of functionality in healthy 338 chondrocytes upon cell culture [21] . These studies mainly focus on the regenerative 339 potential of chondrocytes. Even though the cartilage we extracted was from even and 340 non-injured areas of the joint, the environmental signaling was nevertheless of late-341 stage OA and should be taken into consideration. 342
The transcriptional differences of healthy and osteoarthritic chondrocytes were reported as shown in down-regulation of collagen type 2, aggrecan and SOX9 coupled 345 with up-regulation of collagen type 1 [6,21]. Nevertheless, the de-differentiated 346 chondrocytes showed a high potential for cartilage formation in 3D culture systems. As 347 shown before, imitating the physiological environment of the tissue without further 348 assistance was sufficient for the de-differentiated chondrocytes to re-differentiate [22] . 349
We suggest that the chondrocytes of these OA patients had already experienced this The increased expression of OPN and FABP4 during osteogenic and adipogenic 367 differentiation after 5-aza-dC treatment (Fig 3 and 4) Matrix production was reduced, and marker expression was down-regulated for the 372 first time (Fig 5 and 6) . Additionally, the expression of hypertrophic markers was 373 elevated (Fig 7) . The long-term treatment of OA chondrocytes with 5-aza-dC in our lab did not affect the 395 global DNA-methylation levels (Fig 8) . In the work of Hashimoto et al. the incubation 396 of 5-aza-dC in chondrocytes led to a decrease of DNA methylation of specific CpGs 397 within the IL1b promoter while global DNA demethylation was not shown [28] . In 2017, On the other hand, the chondrogenic differentiation was inhibited. Although the DNMT 425 inhibitor was added every second day for four weeks during the expansion of cells, no 426 global DNA de-methylation could be observed, indicating an additional independent 427 mechanism responsible for the observed effects. 
